Cerebral hyperexcitability and spontaneous epileptiform activity are increasingly recognized as critical modifiers of neurodegenerative disease progression. Clinical observations have long suggested that seizures in dementia accelerate cognitive decline and worsen survival outcomes. However, the precise relationship between ongoing seizure frequency and post-mortem neuropathology has remained unclear until recently. A groundbreaking multicentre study evaluated neuropathological data across 39 Alzheimer's Disease Research Centers over sixteen years. The researchers uncovered striking associations between active seizure status and enhanced brain pathology. Specifically, patients with ongoing seizures exhibited greater neuronal loss, heavier amyloid-beta and tau burden, and earlier mortality compared to counterparts without seizures. Consequently, these findings emphasize that epileptic activity is not merely an incidental late-stage complication. Instead, active epileptogenesis may represent an aggressive biological driver of neurodegeneration. Understanding this neurobiological link allows physicians to approach cognitive disorders with a more comprehensive therapeutic strategy. By prioritizing seizure detection and optimal seizure control, clinicians can potentially mitigate secondary neurotoxic cascades in vulnerable geriatric populations.

The Interplay Between Seizures in Dementia and Accelerated Neuropathology

The bidirectional relationship between epilepsy and cognitive impairment involves complex cellular and network-level mechanisms. Alzheimer's disease pathology promotes neuronal hyperexcitability through amyloid-beta oligomers, abnormal hyperphosphorylated tau deposition, and impaired gamma-aminobutyric acid (GABA)ergic inhibitory interneuron function. Conversely, recurrent epileptiform discharges stimulate the continuous release of neurotoxic proteins and exacerbate synaptic dysfunction across neural circuits. Therefore, this pathological vicious cycle intensifies both structural brain damage and rapid clinical deterioration. In the multicentre cohort analysis, active seizures were strictly defined as seizure episodes occurring within the final year of life. Patients in this active cohort exhibited significantly higher neurofibrillary tangle burden and advanced Braak staging compared to patients whose seizures were quiescent or absent. Furthermore, cerebral amyloid angiopathy and microvascular lesions appeared with markedly higher frequency in individuals with unmanaged seizure activity. These post-mortem neuropathological hallmarks clearly demonstrate that unsuppressed electrical abnormalities actively accelerate underlying proteinopathies. In addition, persistent neuronal firing induces substantial oxidative stress, mitochondrial failure, and persistent neuroinflammation. Microglial activation and reactive astrogliosis further destabilize blood-brain barrier integrity. Consequently, clinicians must recognize that treating epileptic activity in dementia serves a dual purpose: it prevents acute clinical events and substantially decelerates the biological tempo of neurodegenerative decline.

Multicentre Cohort Design and Demographics Across Research Centers

To investigate how seizure activity directly influences neuropathology, investigators analyzed comprehensive autopsy data from 10,474 deceased individuals with dementia. The extensive cohort was derived from 39 specialized Alzheimer's Disease Research Centers between 2005 and 2021. Researchers stratified patients into three distinct groups based on seizure status prior to death: active seizures (occurring within the final 12 months), remote seizures (occurring earlier in disease history but absent in the preceding year), and control participants with no seizure history. The statistical analysis utilized rigorous comparative methods, including Pearson's chi-square tests, Fisher's exact tests, independent t-tests, and analysis of variance. Notably, the study revealed stark demographic and survival differences among the cohorts. Patients with active seizures experienced significantly higher mortality, with a 56% deceased proportion compared to 35% in the remote seizure group and 34% in the control group. Moreover, patients with active seizures reached terminal disease endpoints at a considerably younger age. This premature mortality highlights the severe prognostic impact of unresolved epileptiform activity in neurodegenerative illness. In contrast, patients who achieved seizure control in the remote group demonstrated survival metrics that closely mirrored the control population. Thus, maintaining long-term seizure freedom appears vital for improving overall life expectancy.

Differential Neuropathological Burden and Neurodegeneration Patterns

Post-mortem histological analyses demonstrated distinct pathological divergence across the three study cohorts. Primary neuropathological markers of Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration, and vascular brain injury were systematically evaluated and compared. The researchers observed that active seizures correlated with marked hippocampal sclerosis, severe neocortical thinning, and pronounced neuronal depletion. Furthermore, comorbid pathologies were substantially more prevalent in individuals with unmanaged seizure activity. Mixed pathology, combining dense amyloid plaque pathology with cerebrovascular infarcts and alpha-synuclein aggregates, was frequently identified in the active seizure cohort. Consequently, these individuals demonstrated a lower pathological threshold for severe functional decline and global cognitive impairment. Interestingly, individuals classified in the remote seizure category exhibited pathology that was less extensive than the active seizure cohort, suggesting that effective seizure control might attenuate secondary injury cascades. Although underlying primary protein accumulation continued over time, the secondary neurodestructive processes appeared dampened when seizures were rendered inactive. Therefore, sustained seizure activity clearly exacerbates neurodegenerative cascades, accelerating structural loss across vulnerable corticolimbic networks. These observations provide compelling evidence that electrical stabilization directly protects remaining neural architecture in patients with progressive cognitive disorders.

Clinical Implications of Active Versus Controlled Seizure States

The distinction between active and remote seizure states carries profound implications for daily clinical practice in neurology and geriatrics. Historically, clinicians often viewed late-onset seizures in dementia as benign epiphenomena that required minimal therapeutic escalation. However, the post-mortem data decisively challenge this passive approach. Patients with active seizures demonstrate faster functional decline, worse neuropsychiatric scores, and significantly higher mortality rates. Because seizures in dementia often present atypically—such as transient confusion, unresponsiveness, or subtle automatisms—they frequently escape timely diagnosis and therapeutic intervention. When these subclinical or non-convulsive events remain untreated, continuous hyperexcitability inflicts cumulative cellular damage throughout the vulnerable brain. On the other hand, the comparable survival outcomes between remote seizure patients and seizure-free controls suggest a substantial clinical benefit from effective therapeutic management. Achieving long-term seizure freedom may help preserve residual cognitive reserve and reduce the risk of sudden unexpected death in dementia. Therefore, physicians must maintain a high index of clinical suspicion for covert epileptiform activity. Routine surveillance with electroencephalography (EEG) and aggressive optimization of antiseizure treatment should become standard pillars of comprehensive dementia management.

Practical Strategies for Managing Seizures in Dementia in Routine Practice

Managing seizures in older adults with cognitive impairment requires careful balancing of therapeutic efficacy, tolerability, and pharmacokinetic safety. Age-related physiological changes, multiple medical comorbidities, and altered hepatic and renal drug metabolism complicate pharmacotherapy in this population. First-generation antiseizure medications, such as phenytoin, carbamazepine, and phenobarbital, generally pose substantial clinical risks due to cognitive blunting, hepatic enzyme induction, and extensive drug interactions. In contrast, modern third-generation agents are preferred due to cleaner pharmacokinetic profiles and minimal cognitive interference. Specifically, levetiracetam, lamotrigine, and lacosamide represent favored first-line options for late-onset seizures in neurodegenerative disorders. Levetiracetam offers effective seizure control and has shown potential in reducing network hyperexcitability in Alzheimer's disease models. However, clinicians must monitor for behavioral adverse effects, such as agitation or irritability, in dementia patients. Lamotrigine serves as an excellent alternative with mood-stabilizing properties and favorable cognitive tolerability, although it requires slow dose titration. Additionally, low starting doses and gradual titration schedules minimize sedation and fall risks. Ultimately, collaborative multidisciplinary management involving neurologists, geriatricians, and primary care physicians ensures optimal seizure control while safeguarding patient quality of life.

Frequently Asked Questions

How do active seizures influence post-mortem neuropathology in dementia patients?

Active seizures in dementia significantly correlate with higher neurofibrillary tangle burden, advanced Braak staging, pronounced hippocampal atrophy, and greater microvascular injury. In addition, unsuppressed epileptiform activity accelerates neuronal loss and increases the frequency of mixed neuropathologies, leading to faster clinical deterioration and significantly earlier mortality in affected individuals.

Why are seizures frequently underdiagnosed in individuals with dementia?

Seizures in dementia often present atypically without generalized tonic-clonic motor convulsions. Instead, patients typically experience non-motor focal seizures characterized by transient staring spells, sudden confusion, subtle automatisms, or fluctuating alertness. Clinicians and caregivers frequently mistake these subtle episodic manifestations for routine behavioral fluctuations or worsening dementia symptoms.

What are the preferred antiseizure medications for older patients with dementia?

Modern non-enzyme-inducing antiseizure medications, such as levetiracetam, lamotrigine, and lacosamide, are the preferred therapeutic agents for older patients with dementia. These drugs provide excellent seizure control with favorable pharmacokinetic profiles, minimal drug-drug interactions, and lower risks of cognitive sedation compared to older first-generation agents like phenytoin.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Zawar I et al. The association of seizure control with neuropathology in dementia. Brain. 2025 Jul 07. doi: 10.1093/brain/awaf017. PMID: 39817500.
2. Sen A. Disentangling epilepsy and dementia: more to do, together. Brain. 2025 Jul 07;148(7):2161-2163. doi: 10.1093/brain/awaf225.
3. Zawar I, Quigg M, Johnson EL, Ghosal S, Manning C, Kapur J. Risk factors associated with late-onset epilepsy in dementia and mild cognitive impairment. JAMA Neurol. 2025 Jun 01;82(6):605-613.